Novo Nordisk A/S (NYSE:NVO) Stock Price Down 0.5%

Novo Nordisk A/S (NYSE:NVOGet Free Report) shares traded down 0.5% on Friday . The company traded as low as $128.11 and last traded at $128.20. 1,285,093 shares were traded during trading, a decline of 76% from the average session volume of 5,297,479 shares. The stock had previously closed at $128.90.

Wall Street Analyst Weigh In

A number of research firms recently commented on NVO. TD Cowen boosted their price target on Novo Nordisk A/S from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Monday, December 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday. UBS Group began coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $126.25.

Get Our Latest Research Report on Novo Nordisk A/S

Novo Nordisk A/S Stock Performance

The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a 50-day simple moving average of $120.44 and a 200-day simple moving average of $102.31. The stock has a market cap of $577.81 billion, a P/E ratio of 47.60, a PEG ratio of 2.14 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Research analysts forecast that Novo Nordisk A/S will post 3.36 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th will be given a $0.664 dividend. This represents a yield of 0.9%. The ex-dividend date of this dividend is Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 22.92%.

Institutional Trading of Novo Nordisk A/S

Several hedge funds and other institutional investors have recently made changes to their positions in NVO. Pacific Center for Financial Services grew its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after acquiring an additional 141 shares during the last quarter. Bell Investment Advisors Inc boosted its holdings in Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. CNB Bank bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $26,000. Finally, Citizens National Bank Trust Department boosted its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after acquiring an additional 150 shares during the last quarter. 6.41% of the stock is currently owned by institutional investors.

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.